SummarySpine stereotactic body radiation therapy (SBRT) is now widely accepted for the treatment of vertebral metastases. In the current study, 46 spine SBRT patients had a high-resolution planning at risk volume created around the cord and thecal sac to model the dose delivered by the plans. The median values for the cord and thecal sac sub volumes were 2× higher than recommended by the literature. No myelopathy was seen confirming that current guidelines for SBRT cord dose are conservative.

Introduction {#sec1}
============

Spine stereotactic body radiation therapy (SBRT) has been shown to confer excellent local control and pain control in both the radiation-naïve and reirradiation settings.[@bib1], [@bib2], [@bib3], [@bib4] Spinal cord tolerance in SBRT has been the subject of debate. The incidence of myelopathy is exceedingly low. Attempts to delineate the actuarial risk as well as characterize the cord doses that best correlate with myelopathy have been difficult. Sahgal et al have published extensively on this issue, but given the rarity of this occurrence, to generate an estimate of cord/thecal sac tolerance in spine SBRT, a pooled multiple institutional analysis was performed.[@bib1], [@bib5] Because of differences in target delineation techniques, limitations in reviewing magnetic resonance imaging (MRI) data as well as differences in treatment planning techniques, the authors propose a maximum point dose (Pmax) to the thecal sac of 12.4 Gy for single-fraction regimens, 17 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23 Gy in 4 fractions, and 25.3 Gy in 5 fractions for which the estimated a risk of 5% myelopathy in the radiation-naïve setting.[@bib1] In the reirradiation setting, estimates are understandably much more conservative and depend on the prior dose to the cord.[@bib5]

In contrast, single-institution reports have suggested myelopathy is rare even with doses to the true cord of 15.7 Gy in the reirradiation setting.[@bib4] A recent review of multiple institutions again confirmed that myelopathy was very rare even though the maximum dose to the cord varied widely, to as high as a single point dose of 19 Gy in a single fraction delivery, even in the reirradiation setting.[@bib6] To date, it has been difficult to precisely predict which patients will have myelopathy based on maximum dose to the cord.

In the current single-institution study, we examine dose metrics to both the thecal sac and spinal cord using a high-risk planning at risk volume (PRV) and correlations with toxicity in patients treated with spine SBRT.

Methods {#sec2}
=======

We have previously published on the Mayo Clinic experience with spine SBRT in both the reirradiation and radiation-naïve setting.[@bib4] Between April 2008 and December 2010 (to allow for adequate follow-up of late toxicity), the radiation plans and dose-volume histogram (DVH) parameters from 46 of these patients were exported. These patients were selected because they were the only patients treated during that period with both adequate follow-up and available diagnostic MRI for accurate delineation of the spinal cord and thecal sac. Diagnostic MRI and/or computed tomography (CT) myelograms, from each patient, were fused with the CT planning set to contour the spinal cord and thecal sac. Previous authors have referenced doses to cord, thecal sac, or a PRV. High-resolution PRV structures were created using 1-mm increments for the cord (1-7 mm) and the thecal sac (1-2 mm). Constructing the PRV set enabled examining which cord + PRV margin resulted in distributions similar to thecal sac. Using an alpha/beta of 2 Gy, the biologically equivalent 2-Gy dose (EQD2Gy) maximum (Max(2)\[EQD2Gy\]) and high-dose subvolumes (Dxcc(2)\[EQD2Gy\]) were calculated for x = 0.1 mL to 1.0 mL in 0.1-mL increments from the DVHs.

Toxicities for pain, nausea, myelitis, fatigue, fracture, and radiation necrosis were assessed using the Common Terminology Criteria for Adverse Events, c4.0, criteria. Although clinical data were available in a prospectively collected database, all data were verified by retrospective chart review. Acute and late toxicity data were documented at every follow-up in a prospective manner. Additional information was gleaned from follow up notes and notes documenting effects during the treatment course.

DVH metrics were calculated for all patients in the study using an in-house program, DataMiner. Dependencies of toxicity scores on DVH metrics were examined using receiver operator characteristics (ROC) curve analysis, carried out with R (The R Foundation for Statistical Computing, [www.r-project.org](http://www.r-project.org){#intref0010}) using an in-house program, DataMole.[@bib7], [@bib8] For each DVH metric and toxicity level, an ROC curve was created and the area under the curve calculated. A threshold value for each DVH metric to use in calculating 2 × 2 contingency tables for each toxicity level was determined as the value maximizing the Youden Index on the ROC curve. For each table, the sensitivity, specificity, positive predictive value and negative predictive value were calculated. The significance of the association of groups was calculated using Fisher exact test (*P* \< .01). Differences in mean values for groups with and without toxicity were assessed using *t* tests for significance (*P* \< .05).

Results {#sec3}
=======

Patient demographics {#sec3.1}
--------------------

Forty-six patients were available for analysis ([Table 1](#tbl1){ref-type="table"}). Most patients were male (38/46). Only 9/46 patients had prior external beam radiation therapy to the spine SBRT site. All patients included in the study had a single course of SBRT to the spinal level documented. Sixty-five percent (30/46) patients were treated with a 3-fraction regimen, whereas most of the remaining patients (16/46) received a single-fraction regimen. The most common dose fractionation was 24 Gy/3 fractions.Table 1Demographics of spine SBRT patients (N = 46)Gender Male38 Female8Spine level C spine8 T spine27 L spine11Prior EBRT to SBRT spine level Yes9 No37Dose prescriptions 16 Gy/1 fraction2 18 Gy/1 fraction8 21 Gy/1 fraction1 22 Gy/1 fraction1 24 Gy/1 fraction4 18 Gy/3 fractions2 21 Gy/3 fractions2 24 Gy/3 fractions17 28 Gy/4 fractions1 30 Gy/3 fractions7 35 Gy/5 fractions1[^1]

Acute and late toxicity {#sec3.2}
-----------------------

With respect to acute toxicity, five patients developed pain with spine SBRT (four with grade 1, one with grade 2). Four patients developed nausea (three with grade 1, one with grade 2). Two patients had documented grade 1 fatigue. One patient experienced acute myelitis and one developed acute paresthesias.

No patients developed late myelopathy. This was true even for patients who had more than a 6-month survival with SBRT (37 of 46 patients lived beyond 6 months from the end of SBRT). The patient who initially developed acute myelitis passed away 17.5 months after spine SBRT with no recurrence in the area treated and no symptoms of myelopathy. She died of unrelated causes. Two patients experienced vertebral compression fracture and one patient developed osteoradionecrosis. Characteristics of the patients with acute and late toxicities are further characterized in [Table 2](#tbl2){ref-type="table"}.Table 2Demographics of spine SBRT patients with acute and late toxicityToxicityCTCAE gradeGenderPrior RTSpine levelSBRT dose/fractionationFatigue1MaleNoT924 Gy/3 fractionsFatigue1FemaleNoT630 Gy/3 fractionsNausea1MaleYes (54 Gy/30 fractions)L524 Gy/3 fractionsNausea1MaleNoT10-1124 Gy/3 fractionsNausea1MaleNoT1018 Gy/1 fractionNausea2MaleNoL218 Gy/1 fractionPain1MaleYes (20 Gy/5 fractions)T5-630 Gy/3 fractionsPain2MaleNoT10-T1130 Gy/3 fractionsPain1MaleNoL230 Gy/3 fractionsPain1MaleNoT318 Gy/1 fractionPain1FemaleNoC724 Gy/3 fractionsMyelitis3FemaleNoC624 Gy/3 fractionsParesthesia3MaleNoC522 Gy/1 fractionFracture3MaleNoL218 Gy/1 fractionFracture3MaleNoL324 Gy/1 fractionRadionecrosis3MaleNoT1224 Gy/3 fractions[^2]

Dosimetry and correlation with toxicity {#sec3.3}
---------------------------------------

The mean and median values for the Max(2)\[EQD2Gy\] to the research cord (0, 1, 2, 3, 4, and 5 mm) and to the thecal sac (0, 1, and 2 mm) were calculated. Sample delineation of these structures are shown in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}. The median values of the Max(2)\[EDQ2Gy\] to the spinal cord and thecal sac were 38.5 Gy (range, 7.9-67.9 Gy) and 67.7 Gy (range, 15.5-155.8 Gy), respectively. Distribution of Max(2)\[EQD2Gy\] values for the thecal sac corresponded most closely to spinal cord + 3.5-mm margin ([Figure 3](#fig3){ref-type="fig"}). These values were plotted against the Pmax values published by Sahgal et al[@bib1] in [Figure 4](#fig4){ref-type="fig"}. Our median values for high-dose subvolumes (Dxcc(2)\[EQD2Gy\] were two times higher than the doses for 5% predicted distribution of Max(2)\[EQD2Gy\] values for the PRV 1 and 2 mm were also evaluated. These values were also plotted against the suggested Pmax values[@bib1] in [Figure 4](#fig4){ref-type="fig"}. Our median values for high-dose subvolumes (Dxcc(2)\[EQD2Gy\] in PRV 1 mm and 2 mm were two times higher than the doses for 5% predicted.Figure 1Sample thecal sac 0-, 1-, and 2-mm structures with sample dose-volume histogram.Figure 2Sample cord 0-, 1-, 2-, 3-, 4-, 5-, 6-, and 7-mm structures with sample dose-volume histogram.Figure 3Determining thecal sac dose correlation with spinal cord expansion margin. EQ2Gy, equivalent dose in 2 Gy/fraction; Max(2), maximum dose in 2 Gy equivalent fractions to the spinal cord or thecal sac.Figure 4Myelopathy risk per Sahgal et al and Mayo Clinic minimum EQD2 to thecal sac. 2GyEQ, dose in equivalent 2-Gy fractions; EQ2Gy, biologically equivalent dose in 2-Gy fractions.

The patients who developed myelitis and paresthesia each had a Max(2)\[EQD2Gy\] to the cord of 54.7 Gy and 24.8 Gy, respectively. The Max(2)\[EQD2Gy\] levels to the thecal sac were 72 Gy and 92.7 Gy. Neither patient had prior radiation therapy to the sites treated. Both patients had complete resolution of symptoms within 1 month of treatment.

Spine SBRT was very well-tolerated and acute effects were uncommon, as described previously. The most common acute events were acute back pain (5/46 patients) and nausea (4/46 patients). ROC analysis demonstrated freedom from pain ≥1 was significant for cord Dxcc\[EQ2Gy\] ≤ volume (×) dependent thresholds. Cord D2cc\[EQ2Gy\] ≤ 15.2 Gy was most significant (Fisher exact test \<0.0004) with highest ROC area under the curve (0.85). Thecal sac D0.1cc\[EQD2Gy\] ≥29.3 Gy was a significant indicator for nausea ≥1.

Local control and overall survival {#sec3.4}
----------------------------------

Median follow-up was 14 months and median survival from the end of SBRT spine treatment was also 14 months (range, 1-64 months). At the time of analysis, 34 of 46 patients had died of causes unrelated to spine SBRT. Only one patient of 46 in the current series had documented local progression.

Discussion {#sec4}
==========

The current study raises questions about the sensitivity and tolerance of the spinal cord to high doses of radiation. Despite our patients receiving 2 times the limit that may confer a 5% or greater risk of myelopathy, we did not observe any patients with this complication after spine SBRT. The majority of our patients lived well beyond 6 months with adequate follow-up to assess for these complications.

The seminal study in delineating the risk of myelopathy from spine SBRT was derived from Sahgal et al\'s retrospective review.[@bib1] In that series, spine metastases SBRT databases from MD Anderson Cancer Center, University of Toronto, and University of California at San Francisco were used to identify a cohort of 66 controls and nine patients who developed myelopathy. In that study, median survival was 15 months, which is comparable to our current patient population. Normalized biological equivalent dose or 2 Gy biologically equivalent doses (nBED) was calculated and a logistic regression model was generated to predict 1% and 5% radiation myelopathy. This study suggested that the maximum dose to the thecal sac (nBED Gy2/2) for a single-fraction spine SBRT treatment was 12.4 Gy and 20.3 Gy for a 3-fraction regimen. However, this study is limited by the heterogeneous population across three different institutions and that 7/9 radiation myelopathy patients had dose parameters to the thecal sac that were well below the dose constraints proposed by the authors. The authors also report that the thecal sac actually corresponds to a cord PRV of the cord + 1.5-mm margin, which is more rigorous than our correlation of dose that may reflect contouring differences in the thecal sac between our institutions.

In the current study, our maximum thecal sac doses were twice those reported by Sahgal et al. The median values for high dose subvolumes (Dxcc(2)\[EQD2Gy\] assuming a 2-mm PRV to more closely align with the suggested guidelines were two times higher than the doses for 5% predicted. We have previously reported on 85 spine lesions treated with SBRT in 66 patients with a median follow-up of 8.2 months, none of whom developed myelopathy. The 46 patients included in this study were from the same cohort who had spinal cord and thecal sac contours available for analysis and with further follow-up and median survival of 14 months, there were still no patients who have developed myelopathy. The risk of myelopathy is truly unknown. One recent review examined 1400 patients, mostly reported in retrospective reviews, and proposed that the risk of myelopathy is less than 1%.[@bib9] Chang et al demonstrated no myelopathy with a 21.3-month median follow-up among 63 patients treated with spine SBRT on a phase 1/2 trial.[@bib10] The University of Pittsburgh has extensive experience, with 1075 patients treated with spine SBRT between 1996 and 2005.[@bib11] In that series, they identified only 6 patients who developed late radiation myelopathy.[@bib11] The low incidence of myelopathy may be correlated with poor survival in spinal metastases.

In the past 10 years, chemotherapy has markedly improved systemic control and radiation oncologists are entering an era of aggressive oligometastatic treatment. Median survival after spine SBRT varies but has been reported to be as high as 30 months.[@bib12] However, survival in spinal metastases depends on a variety of factors, including performance status, neurological compromise before treatment, control of the primary and systemic disease, histology, age, and comorbidities. A recent study generated a recursive partitioning study for predicting survival after SBRT.[@bib13] Their model of 174 patients focused on favorable histologies (breast and prostate) and unfavorable histologies (renal cell, melanoma, sarcoma) as well as gender, age, Karnofsky performance scale, primary control, extraosseous metastases, time from primary diagnosis, dose of SBRT, extent of spine disease, and prior spine surgery. The limitation of this study was its short median follow-up of 8.9 months. Class 1 patients were defined as time to diagnosis of spinal metastasis from primary disease \>30 months, Karnofsky performance scale \>70 and had a median survival of 21.1 months. Class 3 patients were diagnosed \<30 months from initial primary diagnosis and age \>70 with a median survival of 2.4 months. Class 2 had a median survival of 8.7 months. The difference in median survival between radiation-resistant and radiosensitive disease was 11 and 14 months, respectively.[@bib13] In the current study, 75% of the patients had already died at the time of analysis after spine SBRT despite excellent local control.

Given the low incidence of myelopathy and variable survival of patients after spine SBRT, it is very difficult to definitively correlate dosimetric data with adverse outcomes and to accurately predict which patients may develop myelopathy. Our study is limited by small numbers as well as its retrospective nature. However, it does confirm that adherence to current guidelines confers a low risk of myelopathy and that in patients whose survival may be limited but who may benefit from spine SBRT, such as in the reirradiation setting, the risk of myelopathy may be low even if cord limits are above current recommendations. Prospective trials such as Radiation Therapy Oncology Group 0631 will help provide insight into ongoing debates about the safety and tolerability of spine SBRT and possible clinical predictors of rare events such as late radiation myelopathy.
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[^1]: EBRT, external beam radiation therapy; SBRT, stereotactic body radiation therapy.

[^2]: CTCAE, Common Terminology Criteria for Adverse Events; SBRT, stereotactic body radiation therapy.
